Clinical Trial

Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) . Participants will take the assigned study drug (either tollB-001 Tablets or placebo) once daily orally for 4 weeks, follow up for 1 week.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-05.
Trial Details
NCT Number NCT07408024
Lead Sponsor Toll Biotech Co. Ltd. (Beijing)
Conditions Rheumatoid Arthritis (RA)
Enrollment 24 participants
Start Date 2025-09-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-17